Inimmune Commences Pivotal Phase 2 Allergy Trial of INI-2004 in Allergic Rhinitis Patients

Inimmune Corporation ("Inimmune"), a clinical-stage biotechnology company focused on developing innovative immunotherapies, ...

Clarametyx Biosciences Announces Positive Topline Data From Phase 2a Study Evaluating CMTX-101 in Cystic Fibrosis

Clarametyx today announced positive topline data from a Phase 1b/2a trial evaluating its novel antibody therapy, CMTX-101, in cystic fibrosis (CF).
Nasdaq

RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...
Business Wire

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...
Nasdaq

Ventyx Biosciences Reports Positive Phase 2a Study Results for VTX3232 in Early-Stage Parkinson's Disease

Ventyx Biosciences announced positive results from its Phase 2a study of VTX3232, an NLRP3 inhibitor, demonstrating safety and tolerability in patients with early-stage Parkinson's disease. The study ...
Forbes

Phase 2 Study Shows Opdivo-Yervoy Highly Effective In Colon Cancer

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. The treatment consisted of two cycles of immunotherapy before ...

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints ...
Business Insider

vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

HIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2 clinical study protocol developed in ...